Citation

Laux G, Schuler P, Bruns S. Psychopharmakotherapie 2000; 7(4): 162-167.

Copyright

(Copyright © 2000, Wissenschaftliche-Verlagsgesellschaft)

DOI

unavailable

PMID

unavailable

Abstract

The specific noradrenergic antidepressant reboxetine was further characterised in two observational studies involving 5 292 patients (793 hospitalised and 4499 outpatients). The demographic data of both groups of patients were comparable. However, the hospitalised patients were very more severely affected with a total Clinical Global Impression (CGI) score of 5,1 (versus 4,6 of the outpatients). The mean dose of reboxetine was 6,3 mg/day over the observational period of about 4 weeks. The incidence of withdrawals due to adverse events was 10.5% in the hospitalised group and 7.8 % in the outpatient group. Blood pressure was not affected in the total sample. One case of suicide was observed. Suicidal tendencies according to the Montgomery-Asberg Depression Rating and Self-evaluation Depression Scales (MADRS and SDS) were relevantly decreasing over the observational period. After 4 weeks of therapy, 58,7 % of the outpatients and 59,1 % of the hospitalised patients (evaluable cases) were rated as much or very much improved in the CGI-scale impression (CGI) scale, item 2.

Language: en

Keywords

antidepressant agent; article; clinical practice; depression; Depression; drug induced disease; drug withdrawal; hospital patient; human; observation; Observational study; outpatient; reboxetine; Reboxetine; Tolerability